U.S. markets closed

Big Rock Partners Acquisition Corp. (BRPA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.68+1.82 (+5.90%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close30.86
Open41.00
Bid32.09 x 800
Ask33.28 x 1000
Day's Range30.51 - 41.00
52 Week Range10.50 - 76.99
Volume59,843
Avg. Volume31,377
Market Cap87.841M
Beta (5Y Monthly)0.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia
      PR Newswire

      NeuroRx and Georgian Ministry of Health Agree to Initiate Expanded Access Program of ZYESAMI (aviptadil acetate) for COVID-19 Respiratory Failure in Georgia

      NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Program (EAP) of its phase 3 drug, ZYESAMI (aviptadil acetate) for critically-ill citizens of Georgia with COVID-19 Respiratory Failure. The EAP will be conducted in collaboration with Denk Pharma Georgia, Georgia's primary pharmaceutical distributor, and under the auspices of the Potomac Institute of Policy Studies and the Richard G. Lugar Center for Public Health Research, a research facility funded by the U.S. Defense Threat Reduction Agency and named in honor of former U.S. Senator Richard G. Lugar to support international research efforts in its endeavor to stop global diseases.

    • Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team
      PR Newswire

      Dr. Anthony Fauci Confirms ZYESAMI Phase 3 Trial with Remdesivir at Press Briefing by White House COVID-19 Response Team

      Dosing of the first patient in a phase 3 clinical trial of ZYESAMI (aviptadil acetate) was announced by the National Institutes of Health (NIH) last week. The trial, designated as ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (TESICO) (www.clinicaltrials.gov NCT04843761), will study ZYESAMI to treat severely ill COVID-19 patients. The study will be carried out across the United States as part of the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to prioritize and accelerate development of the most promising COVID-19 treatments. NeuroRx is designated by NIH as an industry partner in this initiative, one of the first US small businesses to be so-designated. Please refer to NIH's news release for more details.

    • NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development
      PR Newswire

      NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development

      The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx's ability or commitment to deliver a safe, effective, and stable lifesaving drug on a worldwide basis. However, NeuroRx was obligated to disclose Relief's nonpayment of development costs required under the signed collaboration agreement.